

POST-TEST

Recent Developments in the Management of Relapsed/Refractory Multiple Myeloma from ASH 2025: BCMA-Targeted Therapy and Investigational Agents — Microlearning Activity 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In the DREAMM-7 and DREAMM-8 studies, ocular events associated with belantamab mafodotin were _____.**
 - Irreversible in most cases
 - Reversible in most cases**
 - Not experienced by a majority of patients
- What was the approximate hazard ratio for progression-free survival in the Phase III MajesTEC-3 study evaluating teclistamab/daratumumab versus investigator's choice of dexamethasone/pomalidomide or dexamethasone/bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM)?**
 - 0.17**
 - 0.39
 - 0.65
 - 0.80
- Which of the following drug types best reflects the mechanism of action of sonrotoclax?**
 - CELMoD (cereblon E3 ligase modulator)
 - Proteasome inhibitor
 - Bcl-2 inhibitor**
 - Immunomodulatory agent
- What was the approximate overall response rate in the 1.9 mg/kg and 1.4 mg/kg dosing cohorts in the DREAMM-9 study evaluating belantamab mafodotin/bortezomib/lenalidomide/dexamethasone for transplant-ineligible patients with newly diagnosed MM?**
 - 50%
 - 75%
 - 100%**